154 related articles for article (PubMed ID: 28594244)
1. Acute cholinergic syndrome in a patient with mild Alzheimer's type dementia who had applied a large number of rivastigmine transdermal patches on her body.
Suzuki Y; Kamijo Y; Yoshizawa T; Fujita Y; Usui K; Kishino T
Clin Toxicol (Phila); 2017 Nov; 55(9):1008-1010. PubMed ID: 28594244
[TBL] [Abstract][Full Text] [Related]
2. Use of pralidoxime without atropine in rivastigmine (carbamate) toxicity.
Hoffman RS; Manini AF; Russell-Haders AL; Felberbaum M; Mercurio-Zappala M
Hum Exp Toxicol; 2009 Sep; 28(9):599-602. PubMed ID: 19755437
[TBL] [Abstract][Full Text] [Related]
3. Improvement in behavioral and psychological symptoms of dementia by rivastigmine patch in a group of Italian elderly patients with Alzheimer's disease.
Servello A; Ettorre E; Cacciafesta M
Panminerva Med; 2017 Sep; 59(3):275-277. PubMed ID: 28665099
[No Abstract] [Full Text] [Related]
4. Improper Application of a Rivastigmine Patch to the Back of the Neck Induced Toxic Symptoms.
Matsuzono K; Mita Y; Imai G; Fujimoto S
Intern Med; 2023 Nov; 62(21):3247-3250. PubMed ID: 36948626
[TBL] [Abstract][Full Text] [Related]
5. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.
Dhillon S
Drugs; 2011 Jun; 71(9):1209-31. PubMed ID: 21711064
[TBL] [Abstract][Full Text] [Related]
6. Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.
Greenspoon J; Herrmann N; Adam DN
CNS Drugs; 2011 Jul; 25(7):575-83. PubMed ID: 21623641
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study.
Tsuno N; Mori T; Ishikawa I; Bando N; Park H; Matsumoto Y; Mori I; Tanaka M; Hirano T; Nakamura Y
Geriatr Gerontol Int; 2019 Jul; 19(7):571-576. PubMed ID: 30864298
[TBL] [Abstract][Full Text] [Related]
8. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
9. A fatal outcome after unintentional overdosing of rivastigmine patches.
Lövborg H; Jönsson AK; Hägg S
Curr Drug Saf; 2012 Feb; 7(1):30-2. PubMed ID: 22663954
[TBL] [Abstract][Full Text] [Related]
10. [A transdermal patch of rivastigmine (Exelon)].
Salmon E
Rev Med Liege; 2008 Sep; 63(9):570-1. PubMed ID: 19051514
[TBL] [Abstract][Full Text] [Related]
11. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease.
Winblad B; Machado JC
Expert Opin Drug Deliv; 2008 Dec; 5(12):1377-86. PubMed ID: 19040398
[TBL] [Abstract][Full Text] [Related]
12. Reversible Pisa Syndrome Induced by Rivastigmine in a Patient With Early-Onset Alzheimer Disease.
Hsu CW; Lee Y; Lee CY; Lin PY
Clin Neuropharmacol; 2017; 40(3):147-148. PubMed ID: 28452906
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
Darreh-Shori T; Jelic V
Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
[TBL] [Abstract][Full Text] [Related]
14. Real-world Utilisation of the Rivastigmine Transdermal Patches Accompanying the Use of Risk Minimisation Tools in Patients with Dementia.
Reinhardt F; Scarmeas N; Karan R; Veldandi UK; Modali S; Duvvuri K; Pathan RK
Curr Alzheimer Res; 2021; 18(4):273-282. PubMed ID: 34279198
[TBL] [Abstract][Full Text] [Related]
15. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
Farlow MR; Alva G; Meng X; Olin JT
Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
[TBL] [Abstract][Full Text] [Related]
16. From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
Reñé R; Ricart J; Hernández B;
Neurologia; 2014 Mar; 29(2):86-93. PubMed ID: 23684446
[TBL] [Abstract][Full Text] [Related]
17. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.
Pregelj P
Psychogeriatrics; 2012 Sep; 12(3):165-71. PubMed ID: 22994614
[TBL] [Abstract][Full Text] [Related]
19. The donepezil transdermal system for the treatment of patients with mild, moderate, or severe Alzheimer's disease: a critical review.
Buck A; Rezaei K; Quazi A; Goldmeier G; Silverglate B; Grossberg GT
Expert Rev Neurother; 2024 Jun; 24(6):607-614. PubMed ID: 38785454
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
